Zoltán Gasztonyi

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 341 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Roman Hájek, Tamás Masszi, Maria Teresa Petrucci et al. · Leukemia · 2016 · 119 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

The Hungarian Periconceptional Service as a Model for Community Genetics

Andrew E. Czeizel, M. Dobó, István Dudás et al. · Public Health Genomics · 1998 · 19 citations

Medicine, Obstetrics, Genetic Counseling +15